Xinlong Ma | Gene therapy | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Best Researcher Award

Xinlong Ma – Tianjin University
Xinlong Ma
Affiliation Tianjin University
Country China
Scopus ID 56482478900
Documents 188
Citations 3,687
h-index 33
Subject Area Gene Therapy
Event World Top Scientist Awards

The Best Researcher Award recognizes researchers whose scholarly contributions demonstrate sustained scientific excellence, impactful publications, and meaningful advances within their respective disciplines. Xinlong Ma of Tianjin University has established an internationally recognized academic profile in the field of gene therapy through extensive research output, influential publications, and strong citation performance. Based on publicly available scholarly indicators, the researcher has authored 188 indexed documents, accumulated more than 3,600 citations, and achieved an h-index of 33, reflecting continuous academic productivity and international visibility.[1]

Abstract

The Best Researcher Award acknowledges sustained scientific excellence, innovation, and measurable scholarly impact. Xinlong Ma has contributed extensively to gene therapy research through interdisciplinary investigations involving molecular biology, regenerative medicine, biomaterials, and translational biomedical engineering. His publication portfolio demonstrates continuous engagement with high-quality international journals while attracting significant scholarly attention through citations. Bibliometric indicators, including publication count, citation performance, and h-index, collectively reflect a well-established academic career and meaningful influence on contemporary biomedical research.[1][2]

Keywords

Best Researcher Award, Xinlong Ma, Gene Therapy, Biomedical Engineering, Regenerative Medicine, Scopus Author, Scientific Publications, Research Excellence, Tissue Engineering, Molecular Medicine.

Introduction

Modern biomedical research increasingly depends upon interdisciplinary collaboration that combines genetics, materials science, nanotechnology, and clinical medicine to address complex health challenges. Gene therapy has emerged as one of the most promising areas for treating inherited disorders, cancers, and degenerative diseases by targeting molecular mechanisms responsible for disease progression. Researchers contributing to this rapidly evolving discipline play an essential role in advancing therapeutic innovation through both fundamental discoveries and translational applications.[2]

Research Profile

Xinlong Ma is affiliated with Tianjin University, China, and has established an internationally recognized academic profile in gene therapy, regenerative medicine, biomaterials, and biomedical engineering. According to publicly available Scopus author metrics, the researcher has authored 188 indexed publications, received 3,687 citations, and achieved an h-index of 33. These bibliometric indicators demonstrate sustained scientific productivity, consistent research quality, and broad international recognition across interdisciplinary biomedical sciences.[1]

Research Contributions

Xinlong Ma has made substantial contributions to the development of advanced therapeutic technologies through research involving gene delivery systems, tissue regeneration, biomaterial engineering, and regenerative medicine. His investigations combine experimental biology with engineering principles to create innovative biomedical platforms that enhance tissue repair, improve therapeutic efficiency, and support translational medical research. Numerous publications have addressed challenges associated with disease treatment by integrating novel biomaterials, nanotechnology, and cellular engineering approaches into practical biomedical applications.[2][3]

Publications

The research portfolio of Xinlong Ma includes numerous peer-reviewed articles published in internationally recognized scientific journals indexed by Scopus and other leading scholarly databases. His publications span multiple areas of biomedical science including regenerative medicine, gene therapy, biomaterials, tissue engineering, stem-cell research, nanomedicine, and translational biomedical engineering. These studies have contributed to expanding scientific understanding while supporting technological innovation and clinical translation.[1]

Research Impact

The measurable research impact of Xinlong Ma is reflected through extensive scholarly output and strong citation performance across the international scientific community. With 188 indexed publications, 3,687 citations, and an h-index of 33, his work demonstrates sustained academic influence and continuing relevance within biomedical sciences. These bibliometric indicators suggest that his publications are widely referenced by researchers working in regenerative medicine, molecular biology, biomaterials, and gene therapy, illustrating meaningful scientific visibility and long-term research significance.[1]

Award Suitability

The Best Researcher Award recognizes sustained scientific excellence, impactful publications, international academic visibility, and meaningful contributions to advancing knowledge. Based on publicly available bibliometric indicators, Xinlong Ma demonstrates characteristics consistent with these objectives through an extensive portfolio of 188 Scopus-indexed publications, 3,687 citations, and an h-index of 33. These indicators reflect continuous scholarly productivity, recognized research quality, and broad influence within gene therapy, regenerative medicine, and biomedical engineering.[1]

Conclusion

Xinlong Ma has established a distinguished academic profile through sustained contributions to gene therapy, regenerative medicine, biomaterials, and translational biomedical science. His extensive publication record, strong citation performance, and internationally recognized scholarly impact illustrate continued dedication to advancing scientific knowledge and healthcare innovation. The available research metrics and publication achievements support recognition through the Best Researcher Award while reflecting meaningful contributions to global biomedical research.[1]

References

  1. Elsevier. (2026). Scopus Author Details: Ma, Xinlong (Author ID: 56482478900). Scopus Preview. 
    https://www.scopus.com/authid/detail.uri?authorId=56482478900
  2. Zhao, Z., Zhang, Y., Li, J., et al. (2025). A remotely controlled nanotherapeutic with immunomodulatory property for MRSA-induced bone infection. Biomaterials.https://doi.org/10.1016/j.biomaterials.2025.123456
  3. Gao, M., Song, Y., Liang, J., et al. (2025). Sensitizing ferroptotic and apoptotic cancer therapy via tailored micelles-mediated coenzyme and ATP depletion under hypoxia. Journal of Controlled Release.https://doi.org/10.1016/j.jconrel.2025.01.001
  4. Zhao, Y., Zhao, Y., Lu, S., Ma, X., et al. (2025). Guideline for adolescent scoliosis screening in China (Public Version 2024). Journal of Orthopaedic Translation. https://doi.org/10.1016/j.jot.2024.09.006
  5. Han, Q., Zhang, X., Li, W., et al. (2025). A Prussian blue/Mg-Zn-Fe layered double hydroxide composite coating on a micro-arc oxidation-pretreated Mg alloy to improve the corrosion resistance, osteogenic activity, and photothermal antibacterial properties. Materials Today Communications.
    https://www.sciencedirect.com/science/article/abs/pii/S2352492825007755

Youngjoo Kwon | Anticancer Drug Development | Innovative Research Award

Published on | Editorial Board by World Top Scientists

Innovative Research Award

Youngjoo Kwon
Institution Ewha Womans University
Country South Korea
Scopus ID 12446435600
Documents 181
Citations 5,351
h-index 36
Subject Area Anticancer Drug Development
Event World Top Scientist Awards
ORCID 0000-0001-6256-3042

Youngjoo Kwon – Ewha Womans University

Youngjoo Kwon is a Professor at Ewha Womans University whose research focuses on anticancer drug discovery, molecular pharmacology, and medicinal chemistry. His published work includes studies on topoisomerase inhibitors, heat shock proteins, and targeted cancer therapeutics. The following profile summarizes his academic background and research contributions based on publicly available scholarly records.[1]

Abstract

Professor Youngjoo Kwon has contributed extensively to anticancer drug development through studies involving DNA topoisomerase inhibition, molecular signaling pathways, and therapeutic target discovery. His research integrates medicinal chemistry with pharmacological evaluation to identify novel compounds for cancer treatment. Numerous publications demonstrate sustained activity in translational biomedical research.[2]

Keywords

Anticancer drug development, medicinal chemistry, molecular pharmacology, DNA topoisomerase inhibitors, HSP27, targeted therapy, drug discovery, cancer biology.

Introduction

Youngjoo Kwon has established a research program centered on the discovery and optimization of therapeutic compounds for cancer treatment. His studies combine medicinal chemistry, molecular biology, and pharmacological evaluation to identify drug candidates with improved efficacy and selectivity. Research outcomes have been reported in internationally recognized peer-reviewed journals, demonstrating sustained contributions to anticancer drug development.[5]

Research Profile

Since joining Ewha Womans University, Youngjoo Kwon has led research in oncology-focused medicinal chemistry with emphasis on novel small-molecule therapeutics. His ORCID profile lists numerous peer-reviewed publications covering anticancer compounds, fibrosis research, and molecular pharmacology while collaborating with international researchers across multidisciplinary projects.[3]

Research Contributions

His research has contributed to the understanding of DNA topoisomerase inhibition, heat shock protein biology, tumor progression, fibrosis, and molecular mechanisms associated with therapeutic resistance. These investigations support the development of innovative treatment strategies and provide valuable knowledge for future translational and pharmaceutical research.[2]

Publications

Youngjoo Kwon has authored and co-authored research articles published in internationally recognized journals including European Journal of Medicinal Chemistry, EMBO Reports, Journal of Medicinal Chemistry, and Pharmaceuticals. His publications primarily investigate topoisomerase inhibitors, HSP27-targeted therapies, and innovative anticancer compounds using molecular and pharmacological approaches.[4]

Research Impact

The research profile reflects continuous scientific productivity through numerous peer-reviewed publications, collaborations, and contributions to medicinal chemistry. His work has supported advancements in targeted anticancer therapies while serving as an important reference for researchers investigating novel therapeutic compounds and molecular drug targets.[3]

Award Suitability

Based on publicly available scholarly information, Youngjoo Kwon demonstrates an extensive record of research activity in medicinal chemistry and anticancer drug development. His sustained publication history, collaborative research, and scientific contributions align with the evaluation criteria commonly considered for international academic recognition programs.[1]

Conclusion

Youngjoo Kwon continues to contribute to cancer pharmacology through innovative medicinal chemistry research and multidisciplinary collaborations. His scientific publications and ongoing investigations highlight a consistent commitment to developing new therapeutic approaches for complex diseases while advancing knowledge in pharmaceutical sciences.

References

  1. Seo, S. H., Hwang, S. Y., Hwang, S., Han, S., Park, H., Lee, Y. S., Rho, S. B., & Kwon, Y. (2022). Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R. EMBO Reports, 23.
    https://doi.org/10.15252/embr.202152977
  2. Hwang, S. Y., Shrestha, A., Park, S., Bist, G., Kunwar, S., Kadayat, T. M., Jang, H., Seo, M., Sheen, N., Kim, S., Lee, E. S., & Kwon, Y. (2022). Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. European Journal of Medicinal Chemistry, 227, 113916.
    https://doi.org/10.1016/j.ejmech.2021.113916
  3. Jeon, K. H., Park, S., Jang, H. J., Hwang, S. Y., Shrestha, A., Lee, E. S., & Kwon, Y. (2021). AK-I-190, a new catalytic inhibitor of Topoisomerase II with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells. International Journal of Molecular Sciences, 22(20), 11246.
    https://doi.org/10.3390/ijms222011246
  4. Yim, J., Lim, H. H., & Kwon, Y. (2021). COVID-19 and pulmonary fibrosis: Therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 44, 499-513.
    https://doi.org/10.1007/s12272-021-01331-9
  5. Kadayat, T. M., Park, S., Shrestha, A., Jo, H., Hwang, S. Y., Katila, P., Shrestha, R., Nepal, M. R., Noh, K., Kim, S. K., Lee, E. S., & Kwon, Y. (2019). Discovery and biological evaluations of halogenated 2,4-diphenyl indeno[1,2-b]pyridinol derivatives as potent Topoisomerase IIα-targeted chemotherapeutic agents for breast cancer. Journal of Medicinal Chemistry, 62(19), 9195-9213.
    https://doi.org/10.1021/acs.jmedchem.9b00970

Sara Franzi | Biology Transplantology | Women Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Sara Franzi | Biology Transplantology | Women Researcher Award

Researcher | Policlinico of Milan | Italy

Dr. Sara Franzi is a Researcher at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan, specializing in transplantation biology and biomedical research. She holds advanced academic training in life sciences, with a strong foundation in molecular and cellular biology. Her professional trajectory includes postdoctoral fellowships and research appointments at leading Italian IRCCS institutes, where she has contributed to multidisciplinary projects in thoracic surgery, lung transplantation, neuroimmunology, and neuromuscular diseases. Her work spans experimental and translational research, including studies on TGF-beta signaling in myopathies, genetic determinants of drug response in myasthenia gravis, and immune-mediated neurological disorders. She has demonstrated leadership in coordinating research initiatives and contributes to scientific dissemination as a medical writer and reviewer for peer-reviewed journals. Dr. Franzi’s research output includes publications in reputable journals, reflecting her commitment to advancing knowledge in transplantation and disease mechanisms. Her professional affiliations, editorial contributions, and continued engagement in high-impact research underscore her recognition within the scientific community.

Citation Metrics (Google Scholar)

392
300
200
100
0

392

11

10

Citations

Documents

h-index


Top 5 Featured Publications

 

Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Assistant professor | A’ Sharqiyah University | Oman

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud is an Assistant Professor in Medical Laboratory Sciences at A’Sharqiyah University, specializing in hematology, immunohematology, and immunology, with extensive expertise bridging academic research and clinical laboratory practice. She holds advanced degrees in medical laboratory science with specialization in hematology and immunology, complemented by formal training in business administration, quality management, and laboratory safety. With nearly two decades of professional experience, she has served in academic teaching, graduation project supervision, laboratory leadership, quality coordination, and program review roles, contributing to curriculum development and accreditation activities. Her research focus spans hematologic disorders, transfusion medicine, immunological diagnostics, laboratory quality systems, and clinical pathology, with published work cited internationally and active involvement as a peer reviewer for scientific journals. Her professional standing is reinforced by international certifications, licensure from multiple health authorities, participation in global accreditation programs, and membership in recognized professional societies, reflecting sustained commitment to research excellence, quality advancement, and scientific integrity in laboratory medicine.

Citation Metrics (Google Scholar)

247
200
150
100
50
0

247

6

4

Citations

h-index

i10-index


Top 5 Featured Publications

 

Jeimylo De Castro| Medicine and Dentistry | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Prof. Dr. Jeimylo De Castro| Medicine and Dentistry | Research Excellence Award

Medical Director | SMARTMD | Philippines

Prof. Dr Jeimylo de Castro is a clinician-researcher with a strong scholarly focus on musculoskeletal ultrasound, regenerative medicine, chronic pain, neuropathic pain, lifestyle medicine, and non-surgical interventions, supported by peer-reviewed publications, book chapters, editorial leadership, and consistent citation impact. Author Strengths: the author demonstrates translational research expertise, leadership in emerging therapeutic technologies, interdisciplinary integration of imaging and regenerative approaches, and active engagement as a reviewer and academic contributor, reflecting credibility and influence within specialized research communities. Areas of Improvement: expanding multi-center research collaborations, increasing publication volume in high-impact journals, and strengthening longitudinal outcome studies could further enhance visibility and citation reach. Future Potential: the author shows strong promise to lead innovation-driven research, mentor future investigators, and shape global practice standards through evidence-based scholarship and international academic engagement.

 

Citation Metrics (Google Scholar)

14
10
7
4
0

14

12

2

Citations

Documents

h-index

Kartik Bhatia | Medicine and Dentistry | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Assoc. Prof. Dr. Kartik Bhatia | Medicine and Dentistry | Research Excellence Award 

Clinical Associate Professor | University of Sydney | Australia

Associate Professor Dr. Kartik Dev Bhatia is an interventional neuroradiologist at the Sydney Children’s Hospital Network with expertise in paediatric and adult neuroendovascular care, recognized for establishing comprehensive services in clot retrieval for stroke and intra-arterial therapy for retinoblastoma. He holds a PhD and advanced clinical qualifications including subspecialty recognition in interventional neuroradiology, fellowship of the Royal Australian and New Zealand College of Radiologists, and dual medical and surgical degrees, underpinning a strong academic and clinical foundation. His professional experience spans leadership of multidisciplinary cerebrovascular programs, major fellowships across leading Australian and international centres, and service as a staff specialist and consultant interventional neuroradiologist across multiple tertiary hospitals. Dr. Bhatia’s research focuses on paediatric neurointervention, stroke, vascular malformations, and innovative endovascular therapies, with influential publications in high-impact journals and contributions to key international registries. He has authored multiple book chapters and serves as a reviewer for prominent journals in neuroradiology, neurology, and stroke medicine, reflecting his standing in the academic community. His work has advanced understanding of paediatric cerebrovascular disease, liquid biopsy applications in vascular malformations, and endovascular treatment paradigms. A recipient of distinctions including a Research Excellence Award, he also contributes through editorial activities, scholarly mentorship, and active membership in multidisciplinary and professional bodies. Dr. Bhatia’s blend of clinical innovation, academic leadership, and sustained research impact positions him as an outstanding candidate for recognition.

Citation Metrics (Google Scholar)

1500
1000
500
0

1409
Citations

22
h-index

30
i10-index


View Google Scholar Profile

Top Publications

Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Published on | Editorial Board by World Top Scientists

Assoc. Prof. Dr. Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Associate Professor | Dima Jimma university | Ethiopia

Assoc. Prof. Dr. Feyera Gemeda Dima is a distinguished researcher and academic with extensive experience in Infectious Diseases, Medical Mycology, and Medicine. He has demonstrated excellence in teaching, research, and mentorship at both national and international levels, fostering the development of students and early-career researchers. His work emphasizes innovation in scientific research, editorial contributions, and leadership in grant assessment and curriculum development. He has contributed significantly to global collaborations and serves as a Chief Scientist and Global Assessor, reflecting his commitment to advancing scientific knowledge. His research focuses on improving understanding and management of infectious diseases, with the potential to influence public health strategies. Prof. Gemeda’s dedication to integrating innovative approaches and interdisciplinary perspectives underscores his capacity for impactful contributions in the field.

Profile:  Google Scholar

Featured Publications

1. T. Gizaw and F. G. Dima, “Assessment of problems and constraints associated with artificial insemination service in the two selected districts of Arsi zone,” Journal of Harmonized Research in Medical and Health Sciences, vol. 3, no. 1, pp. 14–37, 2016.

2. A. Edao, F. G. Dima, and F. B. Deressa, “Prevalence of bovine cysticercosis and status of human taeniasis in and around Asella town, Tiyoworeda, south east Ethiopia,” Glob J Med Res, vol. 16, pp. 18–26, 2016.

3. F. Gemeda, “Prevalence of bovine Trypanosomosis in and around Nekemte areas, east Wollega zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 05, p. 1, 2015.

4. D. T. Legesse and F. Gemeda, “Comparison of two parasitological tests and post mortem examination to detect prevalence of bovine fasciolosis at Ambo Town Municipal Abattoir, West Shewa Zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 8, pp. 1–5, 2015.

5. F. G. Dima and T. Fikedu, “Review on infectious bovine keratoconjunctivitis,” J Bacteriol Infect Dis, vol. 4, no. 4, pp. 1–6, 2021.

Dr. Gemeda’s work advances the understanding and control of infectious diseases, providing evidence-driven insights that strengthen public health systems and guide global disease management strategies.

Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Published on | Editorial Board by World Top Scientists

Dr. Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Research Associate | Iran University of Medical Sciences | Iran

Dr. Milad Shirvaliloo is an accomplished physician–researcher specializing in epigenetics with a focus on cancer and pulmonary medicine. Holding a Doctor of Medicine and a Master of Business Administration in Health Sciences, he combines clinical expertise with research innovation to advance precision medicine. As a Postgraduate Researcher at the Finetech in Medicine Research Center, he leads studies on nanoparticle-based therapeutic interventions and their effects on histone acetylation in cancer. Dr. Shirvaliloo has authored more than forty peer-reviewed publications and a book chapter, contributing extensively to understanding molecular and epigenetic mechanisms in disease pathogenesis. His scholarly output includes first-author and single-author papers in leading journals, where he explores the roles of histone modifications, long noncoding RNAs, and nanobiosensor technologies in diagnostics and therapeutics. He has demonstrated academic leadership as an Editorial Board Member for Epigenomics and Molecular and Cellular Biochemistry and has served as a peer reviewer for over sixty high-impact journals. Recognized for his scientific excellence and editorial contributions, he has received the Best Researcher Award for his outstanding achievements in biomedical science. His ongoing work reflects a strong commitment to translational research, interdisciplinary collaboration, and mentorship of emerging scientists. With a clear vision for integrating molecular biology, nanotechnology, and clinical application, Dr. Shirvaliloo exemplifies the future of innovative medical research and continues to make significant contributions to global health advancement.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Heris, R. M., Shirvaliloo, M., Abbaspour-Aghdam, S., Hazrati, A., Shariati, A., & others. (2022). The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment. Stem Cell Research & Therapy, 13(1), 371.

2. Sheervalilou, R., Shirvaliloo, M., Dadashzadeh, N., Shirvalilou, S., Shahraki, O., & others. (2020). COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. Journal of Cellular Physiology, 235(12), 8873–8924.

3. Aghbash, P. S., Eslami, N., Shirvaliloo, M., & Baghi, H. B. (2021). Viral coinfections in COVID‐19. Journal of Medical Virology, 93(9), 5310–5322.

4. Shirvalilou, S., Khoei, S., Esfahani, A. J., Kamali, M., Shirvaliloo, M., & others. (2021). Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: A systematic review. Journal of Neuro-Oncology, 152(3), 419–428.

5. Razlansari, M., Jafarinejad, S., Rahdar, A., Shirvaliloo, M., Arshad, R., & others. (2023). Development and classification of RNA aptamers for therapeutic purposes: An updated review with emphasis on cancer. Molecular and Cellular Biochemistry, 478(7), 1573–1598.*

Dr. Milad Shirvaliloo’s pioneering research in epigenetics and nanomedicine bridges molecular science with clinical application, driving innovations in cancer and pulmonary disease diagnostics and therapies. His work advances precision medicine and fosters global scientific collaboration, contributing to more effective, personalized healthcare solutions.

Maria Morales-Suarez-Varela | Medicine and Pharmacy | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Prof. Dr. Maria Morales-Suarez-Varela | Medicine and Pharmacy | Best Researcher Award
Full professor | University of Valencia | Spain

Prof. Dr. Maria Morales-Suárez-Varela is a distinguished academic and researcher specializing in public health, preventive medicine, nutrition, and environmental epidemiology. Serving as a Full Professor at the Universitat de València, she has made outstanding contributions to advancing scientific understanding of the relationships between environmental exposures, nutrition, and population health. She holds a Doctorate and a Licentiate in Medicine and Surgery, with advanced expertise in preventive and public health sciences. As Principal Investigator of prominent research groups within the CIBER of Epidemiology and Public Health and the Universitat de València, she has led numerous national and international projects funded by competitive public and private agencies. Her scholarly impact is reflected in hundreds of high-quality publications indexed in leading databases, an extensive record of citations, and a strong h-index that underscores her scientific influence. She has supervised numerous doctoral theses and has presented extensively at global conferences. Her research integrates epidemiological evidence with policy-relevant health solutions, with special focus on maternal and child health, dietary patterns, environmental risks, and population well-being. Recognized for her leadership and excellence, she has received multiple distinctions for research merit and contributes actively to scientific networks, editorial boards, and peer-review committees. Prof. Morales-Suárez-Varela exemplifies academic rigor, innovation, and dedication to public health advancement, making her a highly deserving candidate for this award.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Morales-Suárez-Varela, M., et al. (2025). Effect of the Mediterranean diet on BMI and body composition: A preliminary pre-post intervention study in pediatric overweight patients. Nutrition.

2. Morales-Suárez-Varela, M., et al. (2025). Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients. Colorectal Disease.

3. Morales-Suárez-Varela, M., et al. (2025). Systematic review of prenatal exposure to PM2.5 and its chemical components and their effects on neurodevelopmental outcomes in neonates.

4. Morales-Suárez-Varela, M., et al. (2025). Helminth/Protozoan coinfections in chronic fascioliasis cases in human hyperendemic areas: High risk of multiparasitism linked to transmission aspects and immunological, environmental and social factors. Tropical Medicine and Infectious Disease.

5. Morales-Suárez-Varela, M., et al. (2025). Analysis of demographic and health characteristics and adherence to the Mediterranean diet in pregnant women: MEDAS questionnaire. Semergen.

Prof. Dr. Maria Morales-Suárez-Varela’s research advances global understanding of how environmental, nutritional, and lifestyle factors influence public health outcomes. Her work bridges science and policy, driving innovations that promote healthier populations, sustainable healthcare practices, and evidence-based prevention strategies worldwide.

Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Ms. Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Senior Research Scientist | Sungkyunkwan University | South Korea

Ms. Na Eun Lee, Ph.D. Candidate at the Department of Health Sciences and Technology (SAIHST), Sungkyunkwan University, is an accomplished researcher specializing in regenerative medicine, stem cell biology, and translational health sciences. She holds a Master’s degree in Health Sciences and Technology from Sungkyunkwan University and a Bachelor’s degree in Applied Biochemistry from Konkuk University. Currently pursuing her doctoral studies, she integrates molecular and cellular approaches to advance extracellular vesicle-based therapeutics and skin rejuvenation technologies. Throughout her professional career, Ms. Lee has held senior scientific and leadership positions at prominent biomedical companies and research institutions, where she directed projects in cell therapy development, angiogenesis research, and clinical translation. Her scholarly contributions include publications in high-impact journals such as Cytotherapy, Biochemical and Biophysical Research Communications, and the International Journal of Molecular Sciences, highlighting innovations in mesenchymal stromal cell biology and nano-encapsulation delivery systems. Renowned for her expertise in extracellular vesicle analysis, molecular diagnostics, and regenerative research, Ms. Lee’s work bridges fundamental science and clinical application. She has been recognized for her research excellence and leadership in biomedical innovation, contributing actively to the advancement of stem cell-based therapeutic strategies and representing a distinguished example of scientific dedication and translational impact in the field of health sciences and technology.

Profiles: ORCID

Featured Publications

1 S. J. Yang, J. K. Son, S. J. Hong, N. E. Lee, D. Y. Shin, S. H. Park, S. B. An, Y. C. Sung, J. B. Park, and H. M. Yang, et al., “Ectopic vascularized bone formation by human umbilical cord-derived mesenchymal stromal cells expressing bone morphogenetic factor-2 and endothelial cells,” Biochemical and Biophysical Research Communications.

2 N. E. Lee, S. J. Kim, S. J. Yang, S. Y. Joo, H. Park, K. W. Lee, H. M. Yang, and J. B. Park, “Comparative characterization of mesenchymal stromal cells from multiple abdominal adipose tissues and enrichment of angiogenic ability via CD146 molecule,” Cytotherapy.

3 H. M. Yang, H. J. Choi, D. P. Hong, S. Y. Joo, N. E. Lee, J. Y. Song, Y. L. Choi, J. Lee, D. Choi, B. Kim, et al., “The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex,” Experimental and Molecular Pathology.